CRISPR | Search Results | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Search Results for 'CRISPR'

Cancer treatment using CRISPR-based Genome Editing System

Posted in CRISPR/Cas9 & Gene Editing, Gene Therapy & Gene Editing Development, Genome Biology, tagged cancer metastasis, CRISPR-Cas9, CRISPR-LNP, gene editing on January 9, 2021| Leave a Comment »

Cancer treatment using CRISPR-based Genome Editing System Reporter: Irina Robu, PhD CRISPR, stands for “clusters of regularly interspaced short palindromic repeats” is one of the biggest accomplishments in science of this decade and it is the simplest tool for altering DNA sequences and modifying gene functions. The technology is adapted form the natural defense mechanism […]

Read Full Post »

Novartis uses a ‘dimmer switch’ medication to fine-tune gene therapy candidates

Posted in Alzheimer's Disease, Biomarkers & Medical Diagnostics, Cerebrovascular and Neurodegenerative Diseases, CRISPR alternative for editing genes without cutting, CRISPR applied to Human Germ Line, CRISPR/Cas9 & Gene Editing, Etiology, Gene Therapy & Gene Editing Development, Genome Biology, Genomic Expression, Neurodegenerative Diseases, Open Access Journals, RNA Biology, Scientific Publishing, tagged Alternate splicing, Chronic renal disease, CRISPR-Cas9, gene therapy, Huntington's disease, Spinal muscular atrophy on August 7, 2021| Leave a Comment »

Novartis uses a ‘dimmer switch’ medication to fine-tune gene therapy candidates Reporter: Amandeep Kaur, BSc., MSc. Using viral vectors, lipid nanoparticles, and other technologies, significant progress has been achieved in refining the delivery of gene treatments. However, modifications to the cargo itself are still needed to increase safety and efficacy by better controlling gene expression. […]

Read Full Post »

First single-course ‘curative’ CRISPR Shot by Intellia rivals Alnylam, Ionis and Pfizer

Posted in Biological Networks, Gene Regulation and Evolution, Cardiomyopathy, Cell Biology, Cerebrovascular and Neurodegenerative Diseases, Chemical Biology and its relations to Metabolic Disease, Chemical Genetics, CRISPR alternative for editing genes without cutting, CRISPR/Cas9 & Gene Editing, Frontiers in Cardiology and Cardiovascular Disorders, Genetics & Pharmaceutical, Genome Biology, Liver & Digestive Diseases Research, Population Health Management, Genetics & Pharmaceutical, Proteomics, RNA interference (RNAi) therapeutic, tagged polyneuropathy on February 19, 2021| Leave a Comment »

First single-course ‘curative’ CRISPR Shot by Intellia rivals Alnylam, Ionis and Pfizer Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 2/23/2023 As Novartis pulls back from legacy sickle cell program, Intellia CEO calls the market ‘wide open’ By Annalee ArmstrongFeb 23, 2023 10:10am Intellia announced in its fourth-quarter earnings report that Novartis had ended development of […]

Read Full Post »

CRISPR-Cas9 and the Power of Butterfly Gene Editing

Posted in Behavioral Genetics, CRISPR alternative for editing genes without cutting, CRISPR/Cas9 & Gene Editing, Genome Biology, Microbiologial genetics, Transcriptomics on August 23, 2020| Leave a Comment »

CRISPR-Cas9 and the Power of Butterfly Gene Editing Reporter: Madison Davis Genome editing is a relatively new branch of genetic engineering that utilizes modern technologies in altering, inserting, or deleting selective DNA sequences within cells. CRISPR-Cas9, otherwise known as “Clustered Regularly Interspaced Short Palindromic Repeat”, is a groundbreaking genome editing technique for scientists, as it […]

Read Full Post »

From AAAS Science News on COVID19: New CRISPR based diagnostic may shorten testing time to 5 minutes

Posted in Biomarkers: Inflammation, Cancer Researchers Fighting COVID-19, Coronavirus Gene Expression, COVID-19, COVID-19, COVID-19: Pandemic Surgery Guidance, CRISPR/Cas9 & Gene Editing, Population genetics, Population Health Management, Population Health Management, Genetics & Pharmaceutical, SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus, SARS-CoV-2, Seasonality & Environmental Factors in Resurgence, Treatment Protocols for COVID-19, Virus Infective Acute Respiratory Syndrome: SARS-CoV, tagged #COVID-19, AAAS, coronavirus, CRISPR, CRISPR –Cas9 system for genetic engineering, CRISPR/Cas and crispr, Jennifer Doudna, Molecular Diagnostics, rapid testing, SARS-CoV-2, SARS-CoV-2 Entry Factors, Single-molecule detection, Virus Infective Acute Respiratory Syndrome: SARS-CoV | Tagged COVID-19 on October 11, 2020| Leave a Comment »

From AAAS Science News on COVID19: New CRISPR based diagnostic may shorten testing time to 5 minutes Reporter: Stephen J. Williams, Ph.D. A new CRISPR-based diagnostic could shorten wait times for coronavirus tests. New test detects coronavirus in just 5 minutes By Robert F. ServiceOct. […]

Read Full Post »

Prime Editing as a New CRISPR Tool to Enhance Precision and Versatility

Posted in CAR-T, CRISPR applied to Human Germ Line, CRISPR/Cas9 & Gene Editing, Disease Biology, Gene Therapy & Gene Editing Development, Genetics & Innovations in Treatment, Genome Biology, tagged Broad Institute, CRISPR, CRISPR –Cas9 system for genetic engineering, CRISPR-based gene editing, Editas, gene editing technology platform, genetic engineering, Nature, off target effects, Tay-Sachs on August 29, 2020| Leave a Comment »

Prime Editing as a New CRISPR Tool to Enhance Precision and Versatility Reporter: Stephen J. Williams, PhD CRISPR has become a powerful molecular for the editing of genomes tool in research, drug discovery, and the clinic (see posts and ebook on this site below) Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene […]

Read Full Post »

The Nobel Prize in Chemistry 2020: Emmanuelle Charpentier & Jennifer A. Doudna

Posted in Award Nominations, Cell Biology, CRISPR alternative for editing genes without cutting, CRISPR applied to Human Germ Line, CRISPR/Cas9 & Gene Editing, DNA repair, Gene Therapy & Gene Editing Development, Genetics & Innovations in Treatment, Genetics & Pharmaceutical, Genome Biology, Interviews with Key Opinion Leaders (KOLs), Molecular Genetics & Pharmaceutical, Nobel Prize Winners, Stem Cells for Regenerative Medicine, tagged CRISPR –Cas9 system for genetic engineering, CRISPR Biology • Genome Editing • Gene Drives • DNA Repair • Model and Industrial Organisms • Technology Development • Stem Cells/Cancer • Genome-Wide Screens, CRISPR-based gene editing, CRISPR-Cas9, CRISPR/Cas and base editing, gene editing, gene editing technology platform, Jennifer Doudna, nobel leureates, Nobel Prize, Nobel Prize in Chemistry, Stanford University on October 8, 2020| Leave a Comment »

The Nobel Prize in Chemistry 2020: Emmanuelle Charpentier & Jennifer A. Doudna Reporters: Stephen J. Williams, Ph.D. and Aviva Lev-Ari, PhD, RN The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2020 to Emmanuelle CharpentierMax Planck Unit for the Science of Pathogens, Berlin, Germany Jennifer A. DoudnaUniversity of California, Berkeley, […]

Read Full Post »

Live Conference Coverage AACR 2020 in Real Time: Monday June 22, 2020 Mid Day Sessions

Posted in Biological Networks, Biomedical Measurement Science, Cancer - General, Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Informatics, CAST - Alternative to CRISPR/Cas9, Computational Biology/Systems and Bioinformatics, Conference Coverage with Social Media, CRISPR/Cas9 & Gene Editing, Funding Opportunities for Cancer Research, Genomic Expression, Health Economics and Outcomes Research, Metabolomics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration, tagged #AACR20, AACR, Cancer research, CRISPR –Cas9 system for genetic engineering, CRISPR/Cas and cell & molecular biology, CRISPR/Cas9 modification, metabolome on June 22, 2020| Leave a Comment »

Live Conference Coverage AACR 2020 in Real Time: Monday June 22, 2020 Mid Day Sessions Reporter: Stephen J. Williams, PhD This post will be UPDATED during the next two days with notes from recordings from other talks Follow Live in Real Time using #AACR20 @pharma_BI @AACR Register for […]

Read Full Post »

Genetic variation causes human lupus, systemic lupus erythematosus (SLE)

Posted in Autoimmune Inflammatory DIseases, CRISPR/Cas9 & Gene Editing, Genome Biology, Genomic Endocrinology, Inflammatory Pathophysiology, RNA Biology, Signaling & Cell Circuits, Single Cell Genomics, Single-cell sequencing, Systemic Inflammatory Response Related Disorders, Variation in human protein-coding regions on February 23, 2023| Leave a Comment »

Genetic variation causes human lupus, systemic lupus erythematosus (SLE) Reporter: Aviva Lev-Ari, PhD, RN TLR7 gain-of-function genetic variation causes human lupus Abstract Although circumstantial evidence supports enhanced Toll-like receptor 7 (TLR7) signalling as a mechanism of human systemic autoimmune disease1,2,3,4,5,6,7, evidence of lupus-causing TLR7 gene variants is lacking. Here we describe human systemic lupus erythematosus caused by […]